Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 weeks with a dose increase in nonresponders to 150 mg BID after 4 weeks. The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy). Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003). Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 weeks on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006). Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 weeks. The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%). Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents). Fostamatinib produced clinically-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab. Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.

1st Internal Department MHAT Hristo Botev AD Vratsa Vratsa Bulgaria

Clinica Ematologica DAME University of Udine Udine Italy

Fakultni nemocnice Brno Brno Czech Republic

Hammersmith Hospital London United Kingdom

Instytut Hematologii i Transfuzjologii Warszawa Poland

McMaster University Michael G DeGroote School of Medicine and Canadian Blood Services Hamilton Ontario Canada

Menzies Institute for Medical Research University of Tasmania Launceston Tasmania

Rigel Pharmaceuticals South San Francisco California

University Clinical Center Medical University of Gdańsk Gdańsk Poland

Weill Cornell Medicine New York New York

Wojewódzki Szpital Specjalistyczny im J Korczaka i Akademia Pomorska w Słupsku Slupsk Poland

Wojewódzki Szpital Specjalistyczny im M Kopernika w Łodzi Lodz Poland

Zobrazit více v PubMed

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. PubMed

Zufferey A, Kapur R, Semple J. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16pii:E16. PubMed PMC

Cohen YC, Djulbegovic B, Shamai‐Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630–1638. PubMed

Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–520. PubMed PMC

McMillan R, Durette C. Long‐term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104(4):956–960. PubMed

Brown TM, Horblyuk RV, Grotzinger KM, Matzdorff AC, Pashos CL. Patient‐reported treatment burden of chronic immune thrombocytopenia therapies. BMC Hematol. 2012;12(1):2. PubMed PMC

Matzdorff AC, Arnold G, Salama A, et al. Advances in ITP–therapy and quality of life–a patient survey. PLoS One. 2011;6(11):e27350. PubMed PMC

McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150–154. PubMed

Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–187. PubMed

Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence‐based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. PubMed

Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: Down but not out. Blood. 2018;131:1172. [Epub ahead of print]. PubMed PMC

Grace R, Despotovic J, Bennett C. Physician decision making in selection of second‐line treatments in immune thrombocytopenia in children. Am J Hematol. 2018. [Epub ahead of print]. PubMed PMC

Guidry JA, George JN, Vesely SK, Kennison SM, Terrell DR. Corticosteroid side‐effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83(3):175–182. PubMed

Crowley MT, Costello PS, Fitzer‐Attas CJ, et al. A critical role for Syk in signal transduction and phagocytosis mediated by Fcy receptors on macrophages. J Exp Med. 1997;186(7):1027–1039. PubMed PMC

Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387–402. PubMed PMC

Takada Y, Aggarwal BB. TNF activates Syk protein tyrosine kinase leading to TNF‐induced MAPK activation, NF‐kappaB activation, and apoptosis. J Immunol. 2004;173(2):1066–1077. PubMed

Ozaki N, Suzuki S, Ishida M, et al. Syk‐dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti‐collagen antibody‐induced arthritis. Int Immunol. 2012;24(9):539–550. PubMed

Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of mice and men: an open‐label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154–3160. PubMed

Kunwar S, Devkota AR, Ghimire DKC. Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta‐analysis of randomized controlled trials. Rheumatol Int. 2016;36(8):1077–1087. PubMed

Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303–1312. PubMed

Weinblatt ME, Kavanaugh A, Burgos‐Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve‐week, randomized, placebo‐controlled trial. Arthritis Rheum. 2008;58(11):3309–3318. PubMed

Weinblatt ME, Genovese MC, Ho M, et al. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis Rheum. 2014;66(12):3255–3264. PubMed

Taylor PC, Genovese MC, Greenwood M, et al. OSKIRA‐4: a phase IIb randomised, placebo‐controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015;74(12):2123–2129. PubMed

Genovese MC, van der Heijde DM, Keystone EC, et al. A phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor‐alpha antagonist. J Rheumatol. 2014;41(11):2120–2128. PubMed

Newland A, Lee E‐J, McDonald V, Bussel JB. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25. PubMed

European Medicines Agency . Guideline on the clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia. EMA/CHMP/153191/2013. 20 February 2014.

Page LK, Psaila B, Hamilton JM, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol. 2007;138(2):245–248. PubMed

Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double‐blind, placebo‐controlled trial. Lancet. 2009;373(9664):641–648. PubMed

Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin‐receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894. PubMed

Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 2009;114(18):3899–3908. PubMed PMC

Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. PubMed

Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double‐blind randomised controlled trial. Lancet. 2008;371(9610):395–403. PubMed

Feng R, Liu X, Zhao Y, et al. GPIIb/IIIa autoantibody predicts better rituximab response in ITP. Br J Haematol. 2017. [Epub ahead of print]. PubMed

Skinner M, Philp K, Lengel D, et al. The contribution of VEGF signalling to fostamatinib‐induced blood pressure elevation. Br J Pharmacol. 2014;171(9):2308–2320. PubMed PMC

Davis MI, Hunt JP, Herrgard S, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046–1051. PubMed

Rolf MG, Curwen JO, Veldman‐Jones M, et al. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015;3(5):e00175. PubMed PMC

Lengel D, Lamm Bergstrom E, Barthlow H, et al. Prevention of fostamatinib‐induced blood pressure elevation by antihypertensive agents. Pharmacol Res Perspect. 2015;3(5):e00176. PubMed PMC

Penalver FJ, Jimenez‐Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85(6):400–406. PubMed

Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110(10):3526–3531. PubMed

Cooper N, Stasi R, Cunningham‐Rundles S, et al. The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232–239. PubMed

Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program